UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

Clinical pharmacokinetics, 2010-02, Vol.49 (2), p.71-87

2010

Volltextzugriff (PDF)

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer

British journal of clinical pharmacology, 2022-08, Vol.88 (8), p.3922-3923

2022

Volltextzugriff (PDF)

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

Clinical pharmacokinetics, 2023-08, Vol.62 (8), p.1063-1079

2023

Volltextzugriff (PDF)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Clinical pharmacokinetics, 2019-04, Vol.58 (4), p.431-449

2019

Volltextzugriff (PDF)

A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors

Journal of clinical pharmacology, 2023-05, Vol.63 (5), p.583-592

2023

Volltextzugriff (PDF)

Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study

Clinical pharmacology and therapeutics, 2023-08, Vol.114 (2), p.413-422

2023

Volltextzugriff (PDF)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

Clinical pharmacokinetics, 2021-02, Vol.60 (2), p.235-247

2021

Volltextzugriff (PDF)

Model vs. experiment to predict crop losses

Science (American Association for the Advancement of Science), 2018-12, Vol.362 (6419), p.1122-1122

2018

Volltextzugriff (PDF)

Dose Titration of Ixazomib Maintenance Therapy in Transplant‐Ineligible Multiple Myeloma: Exposure–Response Analysis of the TOURMALINE‐MM4 Study

Clinical pharmacology and therapeutics, 2023-07, Vol.114 (1), p.220-229

2023

Volltextzugriff (PDF)

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study

Clinical pharmacology and therapeutics, 2022-08, Vol.112 (2), p.327-334

2022

Volltextzugriff (PDF)

The effect of grapefruit juice on drug disposition

Expert opinion on drug metabolism & toxicology, 2011-03, Vol.7 (3), p.267-286

2011

Volltextzugriff (PDF)

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Investigational new drugs, 2024-08, Vol.42 (4), p.343-352

2024

Volltextzugriff (PDF)

Mobocertinib: Mechanism of action, clinical, and translational science

Clinical and translational science, 2024-03, Vol.17 (3), p.e13766-n/a

2024

Volltextzugriff (PDF)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Investigational new drugs, 2023-06, Vol.41 (3), p.402-410

2023

Volltextzugriff (PDF)

Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.450-462

2013

Volltextzugriff (PDF)

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

CPT: pharmacometrics and systems pharmacology, 2024-04, Vol.13 (4), p.624-637

2024

Volltextzugriff (PDF)

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer

CPT: pharmacometrics and systems pharmacology, 2022-06, Vol.11 (6), p.731-744

2022

Volltextzugriff (PDF)

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

CPT: pharmacometrics and systems pharmacology, 2022-08, Vol.11 (8), p.1085-1099

2022

Volltextzugriff (PDF)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Clinical and translational science, 2022-05, Vol.15 (5), p.1143-1154

2022

Volltextzugriff (PDF)

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

Journal of clinical pharmacology, 2018-02, Vol.58 (2), p.180-192

2018

Volltextzugriff (PDF)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Clinical pharmacology and therapeutics, 2019-02, Vol.105 (2), p.376-387

2019

Volltextzugriff (PDF)

Descriptive epidemiology of collegiate men's football injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2003-2004

Journal of athletic training, 2007-04, Vol.42 (2), p.221-233

2007

Volltextzugriff (PDF)

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

Clinical pharmacology in drug development, 2020-02, Vol.9 (2), p.214-223

2020

Volltextzugriff (PDF)

Synthesis and Biological Evaluation of Fatty Acyl Ester Derivatives of (−)-2′,3′-Dideoxy-3′-thiacytidine

Journal of medicinal chemistry, 2012-05, Vol.55 (10), p.4861-4871

2012

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model‐Based Support for Body Surface Area‐Based Dosing Over the 2‐ to 16‐Year Age Range

Journal of clinical pharmacology, 2017-09, Vol.57 (9), p.1183-1193

2017

Volltextzugriff (PDF)

1 – 25 von 1.127

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(847)
Mit Volltextzugriff
(946)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.121)
Deutsch
(5)
Japanisch
(2)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(535)
Life Sciences & Biomedicine
(457)
Humans
(258)
Animals
(117)
Biological And Medical Sciences
(114)
Medical Sciences
(61)
Cardiovascular System & Cardiology
(60)
Physical Sciences
(59)
Fundamental And Applied Biological Sciences. Psychology
(58)
Pharmacology & Pharmacy
(47)
Cardiac & Cardiovascular Systems
(46)
Male
(46)
General & Internal Medicine
(43)
Biochemistry & Molecular Biology
(38)
Social Sciences
(38)
Technology
(38)
Medicine, Research & Experimental
(37)
Research & Experimental Medicine
(37)
Neurosciences & Neurology
(36)
United States
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Telephony
(51)
Biology Of Blood And Marrow Transplantation
(22)
Nature
(20)
Neurocritical Care
(20)
Blood
(17)
Stroke
(17)
Journal Of The American College Of Radiology
(15)
The Annals Of Thoracic Surgery
(13)
Transplantation And Cellular Therapy
(13)
Blood Advances
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(20)

Menü

Weitere Dienste

Einstellungen

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors

Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

Model vs. experiment to predict crop losses

Dose Titration of Ixazomib Maintenance Therapy in Transplant‐Ineligible Multiple Myeloma: Exposure–Response Analysis of the TOURMALINE‐MM4 Study

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study

The effect of grapefruit juice on drug disposition

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Mobocertinib: Mechanism of action, clinical, and translational science

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Descriptive epidemiology of collegiate men's football injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2003-2004

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

Synthesis and Biological Evaluation of Fatty Acyl Ester Derivatives of (−)-2′,3′-Dideoxy-3′-thiacytidine

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model‐Based Support for Body Surface Area‐Based Dosing Over the 2‐ to 16‐Year Age Range

Aktive Filter

Suchergebnisse filtern